

Summary of risk management plan for Valganciclovir Cipla 450 mg film-coated tablets

This is a summary of the risk management plan (RMP) for Valganciclovir Cipla 450 mg film-coated tablets. The RMP details important risks of Valganciclovir Cipla 450 mg film-coated tablets, how these risks can be minimised, and how more information will be obtained about Valganciclovir Cipla 450 mg film-coated tablet's risks and uncertainties (missing information).

Valganciclovir Cipla 450 mg film-coated tablet's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Valganciclovir Cipla 450 mg film-coated tablets should be used.

Important new concerns or changes to the current ones will be included in updates of Valganciclovir Cipla 450 mg film-coated tablet's RMP.

I. The medicine and what it is used for

Valganciclovir Cipla 450 mg film-coated tablets is authorised for the induction and maintenance treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS). Valganciclovir is indicated for the prevention of CMV disease in CMV-negative adults and children (aged from birth to 18 years) who have received a solid organ transplant from a CMV-positive donor. It contains valganciclovir as the active substance and it is given by oral route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Valganciclovir Cipla 450 mg film-coated tablets, together with measures to minimise such risks are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;

- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of Valganciclovir Cipla 450 mg film-coated tablets are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Valganciclovir Cipla 450 mg film-coated tablets. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Valganciclovir Cipla 450 mg film-coated tablets.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Valganciclovir Cipla 450 mg film-coated tablets.